Tuesday, March 28, 2023

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control

Siri Lillegraven, MD, MPH, PhD; Nina Paulshus Sundlisæter, MD, PhD; Anna-Birgitte Aga, MD, PhD; et al.


No comments:

Post a Comment